TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Jazz Pharmaceuticals Secures Global Rights to KRAS Inhibitor Program Through Definitive Agreement with Redx Pharma

Thursday, February 08, 2024

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) have recently entered into a definitive agreement, wherein Jazz is set to acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program. This arrangement entails Jazz taking the lead in advancing candidates through IND-enabling studies and assuming responsibility for clinical development, regulatory processes, manufacturing, and commercialization.

Recognizing the challenges in developing molecules to effectively target specific KRAS mutations and the high unmet need for innovation in cancer treatment, both companies aim to combine their expertise to identify and advance the most promising molecules towards clinical trials, thereby expanding Jazz's early-stage oncology pipeline.

Redx, expressed satisfaction with the agreement, highlighting the recognition of their medicinal chemistry expertise. She emphasized that this collaboration not only allows for the advancement of novel KRAS inhibitors but also extends Redx's cash runway into 2025, aligning with their strategy of creating shareholder value through strategic partnerships and non-dilutive funding.

Transaction terms include an upfront payment of $10 million to Redx by Jazz for all rights to the proprietary KRAS inhibitor program, with potential milestone payments totaling up to $870 million based on development, regulatory, and commercial achievements. Additionally, Redx stands to receive mid-single digit percentage royalties on future net sales.

The significance of KRAS inhibitors lies in their potential to address a wide range of cancers, including colorectal, pancreatic, and lung cancers, where KRAS mutations are prevalent. Developing orally bioavailable agents that target multiple mutations presents an opportunity to enhance treatment options for patients beyond the G12C mutation.

As part of the collaboration, Jazz will fund research and preclinical development activities conducted by Redx, aiming to complete IND-enabling studies for both selective and pan-KRAS profiles.

This partnership between Jazz and Redx represents a strategic move to address the pressing need for effective treatments in oncology, utilizing innovative approaches to target KRAS mutations and improve outcomes for cancer patients.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit